Kevin O. Turner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin O. Turner has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Chandra Prakash Gyawali
Division of Gastroenterology Washington University in St. Louis St. Louis Missouri USA
2 shared publications - Joshua A. Sloan
Department of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USA
2 shared publications - Robert Maximilian Genta
Departments of Pathology and Medicine, Baylor College of Medicine, Houston, TX, USA
2 shared publications - Afrin N. Kamal
Department of Gastroenterology, Stanford University School of Medicine, Stanford, USA
1 shared publication - Areeba H. Rizvi
Department of Pathology & Laboratory Medicine, East Carolina University Health Center, Greenville, NC
1 shared publication - Arianne L. Theiss
Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine, Aurora, USA
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Rare Concurrent Findings With Collagenous Gastroduodenitis in a Pediatric Patient
Collagenous gastritis is a rare type of gastritis characterized by thickened subepithelial collagen and chronic inflammatory infiltrate. We describe the unique presentation of a previously healthy 13-year-old girl, who presented with severe fatigue and exertional dyspnea. The gastric and duodenal histologic features were consistent with collagenous sprue, collagenous gastritis, and chronic atrophic gastritis. To the best of our knowledge, the simultaneous presentation of these entities is highly uncommon in children, underscoring the importance of understanding its pathogenesis.
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Open AccessRare Concurrent Findings With Collagenous Gastroduodenitis in a Pediatric Patient
Collagenous gastritis is a rare type of gastritis characterized by thickened subepithelial collagen and chronic inflammatory infiltrate. We describe the unique presentation of a previously healthy 13-year-old girl, who presented with severe fatigue and exertional dyspnea. The gastric and duodenal histologic features were consistent with collagenous sprue, collagenous gastritis, and chronic atrophic gastritis. To the best of our knowledge, the simultaneous presentation of these entities is highly uncommon in children, underscoring the importance of understanding its pathogenesis.
- Open Access
- 16 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (9) , 939-943
Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia
Fanconi anaemia (FA), a rare genetic disorder of DNA repair, predisposes to squamous cell carcinomas of head, neck and oesophagus. We assessed the value of screening esophagogastroduodenoscopy (EGD) in 20 asymptomatic adults (median age 23.5, 65% female) with FA, compared to age‐and sex‐matched non‐FA patients enrolled at a 3:1 ratio. Among 11 FA patients with abnormal oesophageal mucosa, 15% had low‐grade dysplasia, nodular high‐grade dysplasia or squamous carcinoma in situ, 10% had non‐dysplastic Barrett's oesophagus and 30% had columnar epithelium without goblet cells, compared to none in the controls (p < 0.001). Our findings support routine EGD screening of asymptomatic FA patients.
- 16 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (9) , 939-943
Open AccessPrevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia
Fanconi anaemia (FA), a rare genetic disorder of DNA repair, predisposes to squamous cell carcinomas of head, neck and oesophagus. We assessed the value of screening esophagogastroduodenoscopy (EGD) in 20 asymptomatic adults (median age 23.5, 65% female) with FA, compared to age‐and sex‐matched non‐FA patients enrolled at a 3:1 ratio. Among 11 FA patients with abnormal oesophageal mucosa, 15% had low‐grade dysplasia, nodular high‐grade dysplasia or squamous carcinoma in situ, 10% had non‐dysplastic Barrett's oesophagus and 30% had columnar epithelium without goblet cells, compared to none in the controls (p < 0.001). Our findings support routine EGD screening of asymptomatic FA patients.
- Open Access
- 29 June 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (5) , 427-431
Esophageal Lichen Planus
Goals: To better understand the characteristics, treatment approaches, and outcomes of patients with esophageal lichen planus (ELP). Background: ELP is a rare, often unrecognized and misdiagnosed disorder. Data on this unique patient population are currently limited to small, single-center series. Study: A multicenter, retrospective descriptive study was conducted of adults diagnosed with ELP over a 5-year period, between January 1, 2015, and October 10, 2020, from 7 centers across the United States. Results: Seventy-eight patients (average age 65 y, 86% female, 90% Caucasian) were included. Over half had at least 1 extraesophageal manifestation. Esophageal strictures (54%) and abnormal mucosa (50%) were frequent endoscopic findings, with the proximal esophagus the most common site of stricture. Approximately 20% had normal endoscopic findings. Topical steroids (64%) and/or proton pump inhibitors (74%) dominated management; endoscopic response favored steroids (43% vs. 29% respectively). Almost half of the patients required switching treatment modalities during the study period. Adjunctive therapies varied significantly between centers. Conclusions: Given its at times subtle clinical and endoscopic signs, a high index of suspicion and biopsy will improve ELP diagnosis, especially in those with extraesophageal manifestations. Effective therapies are lacking and vary significantly. Prospective investigations into optimal treatment regimens are necessary.
- 29 June 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (5) , 427-431
Open AccessEsophageal Lichen Planus
Goals: To better understand the characteristics, treatment approaches, and outcomes of patients with esophageal lichen planus (ELP). Background: ELP is a rare, often unrecognized and misdiagnosed disorder. Data on this unique patient population are currently limited to small, single-center series. Study: A multicenter, retrospective descriptive study was conducted of adults diagnosed with ELP over a 5-year period, between January 1, 2015, and October 10, 2020, from 7 centers across the United States. Results: Seventy-eight patients (average age 65 y, 86% female, 90% Caucasian) were included. Over half had at least 1 extraesophageal manifestation. Esophageal strictures (54%) and abnormal mucosa (50%) were frequent endoscopic findings, with the proximal esophagus the most common site of stricture. Approximately 20% had normal endoscopic findings. Topical steroids (64%) and/or proton pump inhibitors (74%) dominated management; endoscopic response favored steroids (43% vs. 29% respectively). Almost half of the patients required switching treatment modalities during the study period. Adjunctive therapies varied significantly between centers. Conclusions: Given its at times subtle clinical and endoscopic signs, a high index of suspicion and biopsy will improve ELP diagnosis, especially in those with extraesophageal manifestations. Effective therapies are lacking and vary significantly. Prospective investigations into optimal treatment regimens are necessary.
- 27 May 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (12) , 1465-1466
Editorial: the other bug
LINKED CONTENT: This article is linked to Taillieu et al paper. To view this article, visit https://doi.org/10.1111/apt.17488
- 27 May 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (12) , 1465-1466
Editorial: the other bug
LINKED CONTENT: This article is linked to Taillieu et al paper. To view this article, visit https://doi.org/10.1111/apt.17488
- 12 May 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (2) , 240-250
Non‐oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically
Summary: Background: Non‐oesophageal gastrointestinal eosinophilic diseases (EGID) are considered rare. However, low disease awareness among clinicians and pathologists may contribute to underdiagnosis.Aims: To determine how frequently requests to evaluate for EGID accompany gastrointestinal biopsies and in what proportion of suspected cases pathologists address these requests, either confirming or refuting the clinical suspicion.Methods: All cases in which biopsy requisitions included an explicit suspicion of EGID were extracted from a large clinicopathologic database and manually reviewed for accuracy. The diagnoses for these cases were then analysed to determine whether clinical suspicions were confirmed, refuted or ignored.Results: Eosinophilic oesophagitis (EoE) was suspected in 12.8% of 903,516 patients with biopsies and confirmed in 14.9% of them. A suspicion of eosinophilic gastritis accompanied Helicobacter pylori gastritis, celiac disease and microscopic colitis (in 21.2%, 49.2%, 1% and 6.4% of the cases, respectively).Conclusions: Gastroenterologists and pathologists commonly address and diagnose EoE. In contrast, both clinical suspicion and diagnosis of non‐oesophageal EGID are extremely rare. Increased clinical awareness might result in a better understanding of the epidemiology and improved diagnosis of these still elusive conditions.
- 12 May 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (2) , 240-250
Non‐oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically
Summary: Background: Non‐oesophageal gastrointestinal eosinophilic diseases (EGID) are considered rare. However, low disease awareness among clinicians and pathologists may contribute to underdiagnosis.Aims: To determine how frequently requests to evaluate for EGID accompany gastrointestinal biopsies and in what proportion of suspected cases pathologists address these requests, either confirming or refuting the clinical suspicion.Methods: All cases in which biopsy requisitions included an explicit suspicion of EGID were extracted from a large clinicopathologic database and manually reviewed for accuracy. The diagnoses for these cases were then analysed to determine whether clinical suspicions were confirmed, refuted or ignored.Results: Eosinophilic oesophagitis (EoE) was suspected in 12.8% of 903,516 patients with biopsies and confirmed in 14.9% of them. A suspicion of eosinophilic gastritis accompanied Helicobacter pylori gastritis, celiac disease and microscopic colitis (in 21.2%, 49.2%, 1% and 6.4% of the cases, respectively).Conclusions: Gastroenterologists and pathologists commonly address and diagnose EoE. In contrast, both clinical suspicion and diagnosis of non‐oesophageal EGID are extremely rare. Increased clinical awareness might result in a better understanding of the epidemiology and improved diagnosis of these still elusive conditions.
- Open Access
- 14 July 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (17) , 3519-3529
The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling
Colorectal cancer exhibits aberrant activation of Wnt/β-catenin signaling. Many inhibitors of the Wnt/β-catenin pathway have been tested for Wnt-dependent cancers including colorectal cancer, but are unsuccessful due to severe adverse reactions. FL3 is a synthetic derivative of natural products called flavaglines, which exhibit anti-inflammatory and cytoprotective properties in intestinal epithelial cells, but has not been previously tested in cell or preclinical models of intestinal tumorigenesis. In vitro studies suggest that flavaglines target prohibitin 1 (PHB1) as a ligand, but this has not been established in the intestine. PHB1 is a highly conserved protein with diverse functions that depend on its posttranslational modifications and subcellular localization. Here, we demonstrate that FL3 combats intestinal tumorigenesis in the azoxymethane-dextran sodium sulfate and ApcMin/+ mouse models and in human colorectal cancer tumor organoids (tumoroids) by inhibiting Wnt/β-catenin signaling via induction of Axin1 expression. FL3 exhibited no change in cell viability in normal intestinal epithelial cells or human matched-normal colonoids. FL3 response was diminished in colorectal cancer cell lines and human colorectal cancer tumoroids harboring a mutation at S45 of β-catenin. PHB1 deficiency in mice or in human colorectal cancer tumoroids abolished FL3-induced expression of Axin1 and drove tumoroid death. In colorectal cancer cells, FL3 treatment blocked phosphorylation of PHB1 at Thr258, resulting in its nuclear translocation and binding to the Axin1 promoter. These results suggest that FL3 inhibits Wnt/β-catenin signaling via PHB1-dependent activation of Axin1. FL3, therefore, represents a novel compound that combats Wnt pathway–dependent cancers, such as colorectal cancer. Significance: Targeting of PHB1 by FL3 provides a novel mechanism to combat Wnt-driven cancers, with limited intestinal toxicity.
- 14 July 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (17) , 3519-3529
Open AccessThe Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling
Colorectal cancer exhibits aberrant activation of Wnt/β-catenin signaling. Many inhibitors of the Wnt/β-catenin pathway have been tested for Wnt-dependent cancers including colorectal cancer, but are unsuccessful due to severe adverse reactions. FL3 is a synthetic derivative of natural products called flavaglines, which exhibit anti-inflammatory and cytoprotective properties in intestinal epithelial cells, but has not been previously tested in cell or preclinical models of intestinal tumorigenesis. In vitro studies suggest that flavaglines target prohibitin 1 (PHB1) as a ligand, but this has not been established in the intestine. PHB1 is a highly conserved protein with diverse functions that depend on its posttranslational modifications and subcellular localization. Here, we demonstrate that FL3 combats intestinal tumorigenesis in the azoxymethane-dextran sodium sulfate and ApcMin/+ mouse models and in human colorectal cancer tumor organoids (tumoroids) by inhibiting Wnt/β-catenin signaling via induction of Axin1 expression. FL3 exhibited no change in cell viability in normal intestinal epithelial cells or human matched-normal colonoids. FL3 response was diminished in colorectal cancer cell lines and human colorectal cancer tumoroids harboring a mutation at S45 of β-catenin. PHB1 deficiency in mice or in human colorectal cancer tumoroids abolished FL3-induced expression of Axin1 and drove tumoroid death. In colorectal cancer cells, FL3 treatment blocked phosphorylation of PHB1 at Thr258, resulting in its nuclear translocation and binding to the Axin1 promoter. These results suggest that FL3 inhibits Wnt/β-catenin signaling via PHB1-dependent activation of Axin1. FL3, therefore, represents a novel compound that combats Wnt pathway–dependent cancers, such as colorectal cancer. Significance: Targeting of PHB1 by FL3 provides a novel mechanism to combat Wnt-driven cancers, with limited intestinal toxicity.